Achilles Therapeutics plc Quarterly Operating Income (Loss) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Achilles Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2022 to Q2 2024.
  • Achilles Therapeutics plc Operating Income (Loss) for the quarter ending June 30, 2024 was -$17.8M, a 1.62% increase year-over-year.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2023 was -$75.3M, a 3.99% increase from 2022.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2022 was -$78.4M, a 22.1% decline from 2021.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2021 was -$64.2M, a 90.3% decline from 2020.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$17.8M +$293K +1.62% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-14
Q2 2023 -$18.1M +$2.45M +11.9% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-14
Q2 2022 -$20.5M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.